^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS mutation + STK11 mutation

    i
    Other names: Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19, KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845; 6794
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over3years
    The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer - SMARCA4 co-occur with KEAP1, STK11, and KRAS mutations. SMARCA4-mutant lung cancers may be more sensitive to immunotherapy. https://t.co/kfwMRtYqJn (@AndresFCardonaZ)
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    KRAS mutation • STK11 mutation • KEAP1 mutation • KRAS mutation + STK11 mutation • SMARCA4 mutation
    over3years
    #OncoAlert I was happy to see these data shared - exploration of impact of mutations in STK11 and KEAP1 showing responses to adagrasib independent of these co-mutations in the context of KRAS G12C. #ENA20 #LCSM (@StephenVLiu)
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12 • KRAS mutation + STK11 mutation
    over3years
    #ESMO20 AMG510 data on KRAS G12C (13% #lcsm) promising data in 59 pts, mFU 11.7 m, diarrhea 25%, fatigue/nausea 10%, ORR 32%, DCR 88%, median duration of response 10.9 m, responses even in STK11 co-mutated tumors. Response not related to KRAS AF, PDL1 or TMB or co-mutations (@jsoriamd)
    Clinical • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS mutation + STK11 mutation
    |
    Lumakras (sotorasib)
    over3years
    What's your choice of 1L therapy for metastatic NSCLC with STK11 and/or KEAP1 mutations? Lets assume PD-L1 <50% and concurrent KRASm. #LCSM @n8pennell @JackWestMD @DevikaDasMD @CharuAggarwalMD @PatelOncology @VamsiVelcheti (@notahedge)
    PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • STK11 mutation • KEAP1 mutation • KRAS mutation + STK11 mutation • KEAP1 mutation + KRAS mutation
    almost4years
    #ASCO20 Characterization of 4,712 #KRAS NSCLC cases shows G12C is the most common subtype (40%) and among the different KRAS mutations, differences noted in PDL1, TMB, STK11 and others. Different KRAS mutation = different biology. #OncoAlert (@StephenVLiu)
    Clinical • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS mutation + STK11 mutation